莫西沙星单独及与其他抗菌药物联合应用对BALB/c小鼠耐多药结核分枝杆菌感染的活性。
Activities of moxifloxacin alone and in combination with other antimicrobial agents against multidrug-resistant Mycobacterium tuberculosis infection in BALB/c mice.
作者信息
Fattorini Lanfranco, Tan Dejiang, Iona Elisabetta, Mattei Maurizio, Giannoni Federico, Brunori Lara, Recchia Simona, Orefici Graziella
机构信息
Laboratory of Bacteriology and Medical Mycology, Istituto Superiore di Sanità STA, Rome, Italy.
出版信息
Antimicrob Agents Chemother. 2003 Jan;47(1):360-2. doi: 10.1128/AAC.47.1.360-362.2003.
Abstract
The activity of moxifloxacin was enhanced by the addition of ethionamide but not by that of cycloserine, thiacetazone, capreomycin, para-aminosalicylic acid, or linezolid in BALB/c mice infected with a strain of Mycobacterium tuberculosis resistant to isoniazid, rifampin, and six other drugs. These observations are important for the therapy of multidrug-resistant tuberculosis.
摘要
在感染了对异烟肼、利福平及其他六种药物耐药的结核分枝杆菌菌株的BALB/c小鼠中，加入乙硫异烟胺可增强莫西沙星的活性，但加入环丝氨酸、氨硫脲、卷曲霉素、对氨基水杨酸或利奈唑胺则不能增强其活性。这些观察结果对耐多药结核病的治疗具有重要意义。
相似文献
1
Activities of moxifloxacin alone and in combination with other antimicrobial agents against multidrug-resistant Mycobacterium tuberculosis infection in BALB/c mice.莫西沙星单独及与其他抗菌药物联合应用对BALB/c小鼠耐多药结核分枝杆菌感染的活性。
Antimicrob Agents Chemother. 2003 Jan;47(1):360-2. doi: 10.1128/AAC.47.1.360-362.2003.
2
Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model.莫西沙星可否用于治疗广泛耐药性结核病？来自小鼠模型的答案。
Antimicrob Agents Chemother. 2010 Nov;54(11):4765-71. doi: 10.1128/AAC.00968-10. Epub 2010 Aug 30.
3
In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis.加替沙星对结核分枝杆菌的体外和体内活性
Antimicrob Agents Chemother. 2002 Apr;46(4):1022-5. doi: 10.1128/AAC.46.4.1022-1025.2002.
4
Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model.利福喷汀、莫西沙星或DNA疫苗可改善小鼠潜伏性结核病模型的治疗效果。
Am J Respir Crit Care Med. 2005 Dec 1;172(11):1452-6. doi: 10.1164/rccm.200507-1047OC. Epub 2005 Sep 8.
5
In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis.莫西沙星、左氧氟沙星、加替沙星及利奈唑胺对结核分枝杆菌的体外活性
Int J Antimicrob Agents. 2002 Dec;20(6):464-7. doi: 10.1016/s0924-8579(02)00239-x.
6
Interactions of linezolid and second-line anti-tuberculosis agents against multidrug-resistant Mycobacterium tuberculosis in vitro and in vivo.利奈唑胺与二线抗结核药物对耐多药结核分枝杆菌的体内外相互作用
Int J Infect Dis. 2016 Nov;52:23-28. doi: 10.1016/j.ijid.2016.08.027. Epub 2016 Sep 7.
7
In vitro postantibiotic effects of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis.利福喷汀、异烟肼和莫西沙星对结核分枝杆菌的体外抗生素后效应
Antimicrob Agents Chemother. 2004 Jan;48(1):340-3. doi: 10.1128/AAC.48.1.340-343.2004.
8
Bactericidal activity of moxifloxacin on exponential and stationary phase cultures of Mycobacterium tuberculosis.莫西沙星对结核分枝杆菌对数生长期和稳定期培养物的杀菌活性。
J Chemother. 2009 Apr;21(2):127-34. doi: 10.1179/joc.2009.21.2.127.
9
[Present and future in the use of anti-tubercular drugs].[抗结核药物使用的现状与未来]
Pneumologia. 2011 Oct-Dec;60(4):198-201.
10
Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis.在小鼠结核病模型中，含PA - 824、莫西沙星和吡嗪酰胺的治疗方案具有强大的杀菌和灭菌活性。
Antimicrob Agents Chemother. 2008 Apr;52(4):1522-4. doi: 10.1128/AAC.00074-08. Epub 2008 Feb 19.
引用本文的文献
1
Assessment of tuberculosis drug efficacy using preclinical animal models and in vitro predictive techniques.使用临床前动物模型和体外预测技术评估抗结核药物疗效。
NPJ Antimicrob Resist. 2024 Dec 16;2(1):49. doi: 10.1038/s44259-024-00066-z.
2
Combination of MCL-1 and BCL-2 inhibitors is a promising approach for a host-directed therapy for tuberculosis.联合使用 MCL-1 和 BCL-2 抑制剂是一种有前途的针对结核病的宿主导向治疗方法。
Biomed Pharmacother. 2023 Dec;168:115738. doi: 10.1016/j.biopha.2023.115738. Epub 2023 Oct 19.
3
NSC19723, a Thiacetazone-Like Benzaldehyde Thiosemicarbazone Improves the Efficacy of TB Drugs and .NSC19723，一种类似噻唑酮的苯甲醛缩氨硫脲，可提高抗结核药物的疗效。
Microbiol Spectr. 2022 Dec 21;10(6):e0259222. doi: 10.1128/spectrum.02592-22. Epub 2022 Oct 31.
4
Systematic measurement of combination-drug landscapes to predict in vivo treatment outcomes for tuberculosis.系统测量联合用药格局以预测结核病的体内治疗结果。
Cell Syst. 2021 Nov 17;12(11):1046-1063.e7. doi: 10.1016/j.cels.2021.08.004. Epub 2021 Aug 31.
5
Intracellular Pharmacodynamic Modeling Is Predictive of the Clinical Activity of Fluoroquinolones against Tuberculosis.细胞内药效动力学模型可预测氟喹诺酮类药物治疗结核病的临床疗效。
Antimicrob Agents Chemother. 2019 Dec 20;64(1). doi: 10.1128/AAC.00989-19.
6
d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal.d-环丝氨酸药代动力学/药效学、耐药结核病的敏感性及剂量影响：一场浮士德式的交易。
Clin Infect Dis. 2018 Nov 28;67(suppl_3):S308-S316. doi: 10.1093/cid/ciy624.
7
Assessment of the Additional Value of Verapamil to a Moxifloxacin and Linezolid Combination Regimen in a Murine Tuberculosis Model.评估维拉帕米对莫西沙星和利奈唑胺联合方案在小鼠结核病模型中的附加价值。
Antimicrob Agents Chemother. 2018 Aug 27;62(9). doi: 10.1128/AAC.01354-18. Print 2018 Sep.
8
Therapy of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis.耐多药和广泛耐药结核病的治疗。
Microbiol Spectr. 2017 Mar;5(2). doi: 10.1128/microbiolspec.TNMI7-0042-2017.
9
Successful Treatment of Disseminated Bacillus Calmette-Guérin Disease in an HIV-Infected Child with a Linezolid-Containing Regimen.含利奈唑胺方案成功治疗一名感染HIV儿童的播散性卡介苗病
Case Rep Infect Dis. 2016;2016:1528981. doi: 10.1155/2016/1528981. Epub 2016 Oct 10.
10
本文引用的文献
1
Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis.在鼠结核病模型中，增加莫西沙星每日及每周剂量的杀菌活性。
Antimicrob Agents Chemother. 2002 Jun;46(6):1875-9. doi: 10.1128/AAC.46.6.1875-1879.2002.
2
In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis.加替沙星对结核分枝杆菌的体外和体内活性
Antimicrob Agents Chemother. 2002 Apr;46(4):1022-5. doi: 10.1128/AAC.46.4.1022-1025.2002.
3
Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice.每周一次的利福喷汀和莫西沙星联合方案对小鼠结核分枝杆菌的疗效。
Antimicrob Agents Chemother. 2001 Dec;45(12):3482-6. doi: 10.1128/AAC.45.12.3482-3486.2001.
4
The treatment of multidrug-resistant tuberculosis in Turkey.土耳其耐多药结核病的治疗
N Engl J Med. 2001 Jul 19;345(3):170-4. doi: 10.1056/NEJM200107193450303.
5
Activity of 16 antimicrobial agents against drug-resistant strains of Mycobacterium tuberculosis.16种抗菌剂对结核分枝杆菌耐药菌株的活性
Microb Drug Resist. 1999 Winter;5(4):265-70. doi: 10.1089/mdr.1999.5.265.
6
Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model.几种新型恶唑烷酮类药物在小鼠模型中对结核分枝杆菌的活性。
Antimicrob Agents Chemother. 1999 May;43(5):1189-91. doi: 10.1128/AAC.43.5.1189.
7
rpoB mutations in multidrug-resistant strains of Mycobacterium tuberculosis isolated in Italy.在意大利分离出的耐多药结核分枝杆菌中的rpoB基因突变
J Clin Microbiol. 1999 Apr;37(4):1197-9. doi: 10.1128/JCM.37.4.1197-1199.1999.
8
In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.莫西沙星和克林沙星对结核分枝杆菌的体外及体内活性
Antimicrob Agents Chemother. 1998 Aug;42(8):2066-9. doi: 10.1128/AAC.42.8.2066.
9
Therapy of multidrug-resistant tuberculosis: lessons from studies with mice.耐多药结核病的治疗：来自小鼠研究的经验教训
Antimicrob Agents Chemother. 1993 Nov;37(11):2344-7. doi: 10.1128/AAC.37.11.2344.
10
Activities of poloxamer CRL8131 against Mycobacterium tuberculosis in vitro and in vivo.泊洛沙姆CRL8131对结核分枝杆菌的体内外活性
Antimicrob Agents Chemother. 1995 Jun;39(6):1349-54. doi: 10.1128/AAC.39.6.1349.
Zotero 插件